Biotest Aktiengesellschaft (BIO.DE)
EUR 41.4
(0.49%)
EUR 41.4
(0.49%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 271.9 Million EUR | 117.69% |
| 2022 | 124.9 Million EUR | 54.77% |
| 2021 | 80.7 Million EUR | -37.97% |
| 2020 | 130.1 Million EUR | 1.01% |
| 2019 | 128.8 Million EUR | -4.45% |
| 2018 | 134.8 Million EUR | 9.15% |
| 2017 | 123.5 Million EUR | -39.31% |
| 2016 | 203.5 Million EUR | 44.02% |
| 2015 | 141.3 Million EUR | -37.06% |
| 2014 | 224.5 Million EUR | 8.14% |
| 2013 | 207.6 Million EUR | 12.42% |
| 2012 | 184.66 Million EUR | 10.08% |
| 2011 | 167.76 Million EUR | 1.99% |
| 2010 | 164.48 Million EUR | -22.53% |
| 2009 | 212.32 Million EUR | -3.11% |
| 2008 | 219.13 Million EUR | 42.44% |
| 2007 | 153.84 Million EUR | 9.9% |
| 2006 | 139.98 Million EUR | 11.0% |
| 2005 | 126.1 Million EUR | 21.57% |
| 2004 | 103.72 Million EUR | 6.39% |
| 2003 | 97.49 Million EUR | -15.8% |
| 2002 | 115.78 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 90.6 Million EUR | 31.11% |
| 2024 Q2 | 51.1 Million EUR | -43.6% |
| 2023 Q3 | 166.4 Million EUR | 248.85% |
| 2023 Q1 | 24.7 Million EUR | -44.12% |
| 2023 Q2 | 47.7 Million EUR | 93.12% |
| 2023 Q4 | 69.1 Million EUR | -58.47% |
| 2023 FY | 271.9 Million EUR | 117.69% |
| 2022 Q4 | 44.2 Million EUR | 87.29% |
| 2022 Q3 | 23.6 Million EUR | -23.38% |
| 2022 Q2 | 30.8 Million EUR | 17.56% |
| 2022 Q1 | 26.2 Million EUR | 2481.82% |
| 2022 FY | 124.9 Million EUR | 54.77% |
| 2021 FY | 80.7 Million EUR | -37.97% |
| 2021 Q1 | 23 Million EUR | -39.15% |
| 2021 Q2 | 33 Million EUR | 43.48% |
| 2021 Q3 | 25.8 Million EUR | -21.82% |
| 2021 Q4 | -1.1 Million EUR | -104.26% |
| 2020 FY | 130.1 Million EUR | 1.01% |
| 2020 Q1 | 28.5 Million EUR | -36.1% |
| 2020 Q2 | 37.6 Million EUR | 31.93% |
| 2020 Q3 | 26.2 Million EUR | -30.32% |
| 2020 Q4 | 37.8 Million EUR | 44.27% |
| 2019 Q1 | 19.5 Million EUR | -47.44% |
| 2019 Q3 | 29.3 Million EUR | -17.23% |
| 2019 Q4 | 44.6 Million EUR | 52.22% |
| 2019 FY | 128.8 Million EUR | -4.45% |
| 2019 Q2 | 35.4 Million EUR | 81.54% |
| 2018 Q2 | 33.7 Million EUR | 11.59% |
| 2018 FY | 134.8 Million EUR | 9.15% |
| 2018 Q1 | 30.2 Million EUR | 41.78% |
| 2018 Q3 | 33.8 Million EUR | 0.3% |
| 2018 Q4 | 37.1 Million EUR | 9.76% |
| 2017 Q3 | 41.6 Million EUR | -14.75% |
| 2017 Q2 | 48.8 Million EUR | 313.56% |
| 2017 FY | 123.5 Million EUR | -39.31% |
| 2017 Q4 | 21.3 Million EUR | -48.8% |
| 2017 Q1 | 11.8 Million EUR | -83.12% |
| 2016 Q4 | 69.9 Million EUR | 78.32% |
| 2016 Q2 | 48.4 Million EUR | 5.22% |
| 2016 Q1 | 46 Million EUR | -32.15% |
| 2016 FY | 203.5 Million EUR | 44.02% |
| 2016 Q3 | 39.2 Million EUR | -19.01% |
| 2015 FY | 141.3 Million EUR | -37.06% |
| 2015 Q3 | -19.2 Million EUR | -139.75% |
| 2015 Q4 | 67.8 Million EUR | 453.13% |
| 2015 Q2 | 48.3 Million EUR | 8.78% |
| 2015 Q1 | 44.4 Million EUR | -26.0% |
| 2014 Q4 | 60 Million EUR | 10.09% |
| 2014 FY | 224.5 Million EUR | 8.14% |
| 2014 Q1 | 51.2 Million EUR | -4.3% |
| 2014 Q2 | 58.8 Million EUR | 14.84% |
| 2014 Q3 | 54.5 Million EUR | -7.31% |
| 2013 Q3 | 51.5 Million EUR | -3.2% |
| 2013 FY | 207.6 Million EUR | 12.42% |
| 2013 Q1 | 49.4 Million EUR | -0.53% |
| 2013 Q2 | 53.2 Million EUR | 7.69% |
| 2013 Q4 | 53.5 Million EUR | 3.88% |
| 2012 Q4 | 49.66 Million EUR | 19.38% |
| 2012 FY | 184.66 Million EUR | 10.08% |
| 2012 Q1 | 47.4 Million EUR | 4.5% |
| 2012 Q2 | 46 Million EUR | -2.95% |
| 2012 Q3 | 41.6 Million EUR | -9.57% |
| 2011 FY | 167.76 Million EUR | 1.99% |
| 2011 Q4 | 45.36 Million EUR | 10.37% |
| 2011 Q1 | 38.5 Million EUR | 66.07% |
| 2011 Q3 | 41.1 Million EUR | -3.97% |
| 2011 Q2 | 42.8 Million EUR | 11.17% |
| 2010 Q4 | 23.18 Million EUR | -46.34% |
| 2010 Q3 | 43.2 Million EUR | -5.88% |
| 2010 Q2 | 45.9 Million EUR | -12.07% |
| 2010 FY | 164.48 Million EUR | -22.53% |
| 2010 Q1 | 52.2 Million EUR | -1.92% |
| 2009 Q4 | 53.22 Million EUR | 4.97% |
| 2009 FY | 212.32 Million EUR | -3.11% |
| 2009 Q2 | 54.6 Million EUR | 1.49% |
| 2009 Q1 | 53.8 Million EUR | 0.0% |
| 2009 Q3 | 50.7 Million EUR | -7.14% |
| 2008 FY | 219.13 Million EUR | 42.44% |
| 2007 FY | 153.84 Million EUR | 9.9% |
| 2006 FY | 139.98 Million EUR | 11.0% |
| 2005 FY | 126.1 Million EUR | 21.57% |
| 2004 FY | 103.72 Million EUR | 6.39% |
| 2003 FY | 97.49 Million EUR | -15.8% |
| 2002 FY | 115.78 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| BioNTech SE | 3.21 Billion EUR | 91.554% |
| CureVac N.V. | -70.6 Million EUR | 485.084% |
| Biotest Aktiengesellschaft | 271.9 Million EUR | 0.0% |
| BRAIN Biotech AG | 30.12 Million EUR | -802.663% |
| Formycon AG | 23.3 Million EUR | -1066.702% |
| Heidelberg Pharma AG | 6.6 Million EUR | -4015.903% |
| Medigene AG | 4.39 Million EUR | -6092.211% |